Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages e73-e74

  Hellmann, Matthew D ^a   Reva, Boris ^b   Yu, Helena ^a   Rusch, Valerie W ^c   Rizvi, Naiyer A ^a   Kris, Mark G ^a   Arcila, Maria E ^d,e  

^a Thoracic Oncology Service   (United States)

^b Computational Biology Center ^*  (United States)

^c Thoracic Service   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LOCKED NUCLEIC ACID; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ALLELE; ARTICLE; CANCER STAGING; CANCER SURGERY; CASE REPORT; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HYDROGEN BOND; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; MASS SPECTROMETRY; MUTANT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SMOKING; TREATMENT RESPONSE; WILD TYPE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; POINT MUTATION;

ADENOCARCINOMA; COMPUTER SIMULATION; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925813420     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000221     Document Type: Article

References (5)

1. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011;39:e118.
2. Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 2010;1804:559-566.
3. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-229.
4. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-467.
5. Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010;40:1105-1109.